Transcenta Holding Limited (Stock Code: 6628) has provided a business update regarding its partner Inhibrx Biosciences, Inc. (Nasdaq: INBX), which announced positive topline data from the registrational ChonDRAgon study involving 206 patients with advanced or metastatic, unresectable chondrosarcoma. Ozekibart (INBRX-109), investigated as a single agent compared with placebo, demonstrated a significant progression-free survival benefit. Inhibrx intends to submit a Biologics License Application for U.S. approval by the end of June 2026.
Ozekibart is a tetravalent DR5 agonist antibody designed to leverage tumor-biased cell death induced by DR5 activation. It has received Fast Track designation from the U.S. FDA for metastatic or unresectable conventional chondrosarcoma and orphan drug designation for chondrosarcoma. Transcenta holds exclusive rights to develop and commercialize ozekibart in mainland China, Hong Kong SAR, Macau SAR, and the Taiwan region. Inhibrx is also running expansion cohorts combining ozekibart with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with initial data showing encouraging signs in these indications.
